MEDANTANSEGlobal Health LimitedMinimalNeutral
Announced Fri, 15 May · 11:46 IST

Global Health Limited has informed the Exchange about Copy of Newspaper Publication

MEDANTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.4%1-day move
₹1210.30
prior close
₹1257.90
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0+0.1+0.2+0.2+2.4+2.0+1.9+2.5+2.1+1.5-0.0+0.3+10.9
Up moveDown movePending
AI summary

Global Health Limited (Medanta) published its audited financial results for Q4 and the full year ended March 31, 2026, in Financial Express (English) and Jansatta (Hindi) newspapers on May 15, 2026. Consolidated revenue for FY26 stood at ₹44,102.66 million, up ~19% from ₹36,923.45 million in FY25. Net profit after tax (consolidated) grew to ₹5,540.68 million from ₹4,813.18 million, an increase of ~15%. Basic EPS for FY26 was ₹20.71 versus ₹17.92 in the prior year. Standalone revenue was ₹6,492.77 million with net profit after tax at ₹4,962.01 million. The results were reviewed by the Audit Committee and approved by the Board of Directors on May 14, 2026.

Likely market impact

Strong financial performance with ~19% revenue growth and ~15% profit growth year-on-year signals healthy operational momentum for Medanta. The improved EPS of ₹20.71 could support a positive re-rating of the stock in the near term.